Previous 10 | Next 10 |
2023-06-06 08:19:00 ET HTG Molecular Diagnostics ( HTGM ) -40% . Ucommune International ( UK ) -16% . EZGO Technologies EZGO -8% on $8.5M direct offering . Timber Pharmaceuticals ( TMBR ) -10% . Celestica CLS -8% on pricing secondary sto...
2023-06-05 08:50:32 ET Forza X1 ( FRZA ) +133% . Timber Pharmaceuticals ( TMBR ) +92% Announces FDA Grant of CARC Waiver for TMB-001 Chijet Motor Company ( CJET ) +55% . CIRCOR International ( CIR ) +50% to be bought by KKR in $1.6B deal. ...
The clinical trial of the personalized cancer vaccine EVX-01 met its primary endpoints of safety and tolerability Positive clinical responses were reported in 8 out of 12 EVX-01 treated patients High-quality neoantigens, predicted by AI technology, were associated with longer progression-...
2023-05-31 09:14:48 ET Evaxion Biotech ADS press release ( EVAX ): Q1 GAAP EPS of -$0.24. Cash position: As of March 31, 2023, cash and cash equivalents were $10.2 million as compared to $13.2 as of December 31, 2022. Research and Development expenses were $3.9 million for...
Full read-out of the Phase 1/2a trial of EVX-02 in 10 patients with completely resected melanoma was presented at AACR in April 2023, meeting primary endpoints and demonstrating relapse-free survival in all EVX-02 completers Recent R&D Day highlighted Evaxion´s proprietary genetic ad...
Positive clinical response as demonstrated in 8 out of 12 patients receiving EVX-01 in combination with a checkpoint inhibitor The study met primary endpoints for tolerability and safety COPENHAGEN, Denmark, May 25, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“...
Evaxion developed a genetic adjuvant technology that boosts the immune responses of viral, bacterial and cancer vaccines Preclinically validated for both DNA and mRNA vaccines, and ready for clinical testing Anticipated large market potential for DNA and mRNA vaccines against cancer, vi...
COPENHAGEN, Denmark, May 16, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the discovery and development of AI-powered immunotherapies, today announced that it will hold ...
2023-05-08 10:03:22 ET Gainers: Immuron ( IMRN ) +49% . ANI Pharmaceuticals ( ANIP ) +17% . MiNK Therapeutics ( INKT ) +13% . Evaxion Biotech ( EVAX ) +8% . Predictive Oncology ( POAI ) +8% . Losers: Catalent ( CTLT ) ...
2023-04-27 09:47:28 ET Evaxion Biotech ADS press release ( EVAX ): Q4 GAAP EPS of -$0.98. As of December 31, 2022, cash and cash equivalents were $13.2 million as compared to $32.2 million as of December 31, 2021. Research and Development expenses were $17.1 million f...
News, Short Squeeze, Breakout and More Instantly...
Central AI-Immunology™ Building Block: Evaxion’s proprietary in-house developed building block, EvaxMHC, is used across the AI-Immunology™ platform Improved Performance: Utilizing a state-of-the-art novel deep-learning framework as well as training on public and...
COPENHAGEN, Denmark, July 03, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today issued the following letter to shareholders...
Positive Feedback Received: An International Preliminary Report on Patentability (IPRP) indicates promising prospects for obtaining granted patents and protecting the invention Unique Attributes and Inventiveness: The feedback highlights the distinct and inventive nature of all rele...